Found 4 hits for monomerid = 476772 Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
D(3) dopamine receptor
(Homo sapiens (Human)) | BDBM476772
![PNG](/data/jpeg/tenK47/BindingDB_476772.png) (US10870660, Compound III-128 | US11345716, Compoun...)Show SMILES Cn1c(cccc1=O)C(=O)N[C@H]1CC[C@H](CCN2CCc3nc(OCC(F)(F)F)sc3CC2)CC1 |r,wU:14.15,wD:11.11,(7.66,4.8,;8.99,4.03,;8.99,2.49,;10.33,1.72,;11.66,2.49,;11.66,4.03,;10.33,4.8,;10.33,6.34,;7.66,1.72,;7.66,.18,;6.32,2.49,;4.99,1.72,;3.66,2.49,;2.32,1.72,;2.32,.18,;.99,-.59,;-.34,.18,;-1.68,-.59,;-3.03,.14,;-4.45,-.46,;-4.86,-2.02,;-6.32,-2.49,;-6.32,-4.03,;-7.66,-4.8,;-8.99,-4.03,;-10.33,-4.8,;-11.66,-4.03,;-10.33,-6.34,;-11.66,-5.57,;-4.86,-4.51,;-3.95,-3.26,;-2.42,-3.26,;-1.4,-2.1,;3.66,-.59,;4.99,.18,)| Show InChI InChI=1S/C24H31F3N4O3S/c1-30-19(3-2-4-21(30)32)22(33)28-17-7-5-16(6-8-17)9-12-31-13-10-18-20(11-14-31)35-23(29-18)34-15-24(25,26)27/h2-4,16-17H,5-15H2,1H3,(H,28,33)/t16-,17- | PDB
UniProtKB/SwissProt
antibodypedia GoogleScholar AffyNet ![](/images/AffyNet_logo.png)
| PC cid PC sid UniChem
| US Patent
| 0.120 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
SHIONOGI & CO., LTD.
US Patent
| Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent... |
US Patent US10870660 (2020)
|
More data for this Ligand-Target Pair | |
D(3) dopamine receptor
(Homo sapiens (Human)) | BDBM476772
![PNG](/data/jpeg/tenK47/BindingDB_476772.png) (US10870660, Compound III-128 | US11345716, Compoun...)Show SMILES Cn1c(cccc1=O)C(=O)N[C@H]1CC[C@H](CCN2CCc3nc(OCC(F)(F)F)sc3CC2)CC1 |r,wU:14.15,wD:11.11,(7.66,4.8,;8.99,4.03,;8.99,2.49,;10.33,1.72,;11.66,2.49,;11.66,4.03,;10.33,4.8,;10.33,6.34,;7.66,1.72,;7.66,.18,;6.32,2.49,;4.99,1.72,;3.66,2.49,;2.32,1.72,;2.32,.18,;.99,-.59,;-.34,.18,;-1.68,-.59,;-3.03,.14,;-4.45,-.46,;-4.86,-2.02,;-6.32,-2.49,;-6.32,-4.03,;-7.66,-4.8,;-8.99,-4.03,;-10.33,-4.8,;-11.66,-4.03,;-10.33,-6.34,;-11.66,-5.57,;-4.86,-4.51,;-3.95,-3.26,;-2.42,-3.26,;-1.4,-2.1,;3.66,-.59,;4.99,.18,)| Show InChI InChI=1S/C24H31F3N4O3S/c1-30-19(3-2-4-21(30)32)22(33)28-17-7-5-16(6-8-17)9-12-31-13-10-18-20(11-14-31)35-23(29-18)34-15-24(25,26)27/h2-4,16-17H,5-15H2,1H3,(H,28,33)/t16-,17- | PDB
UniProtKB/SwissProt
antibodypedia GoogleScholar AffyNet ![](/images/AffyNet_logo.png)
| PC cid PC sid UniChem
| | 0.120 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA
| |
Citation and Details
|
More data for this Ligand-Target Pair | |
D(2) dopamine receptor
(Homo sapiens (Human)) | BDBM476772
![PNG](/data/jpeg/tenK47/BindingDB_476772.png) (US10870660, Compound III-128 | US11345716, Compoun...)Show SMILES Cn1c(cccc1=O)C(=O)N[C@H]1CC[C@H](CCN2CCc3nc(OCC(F)(F)F)sc3CC2)CC1 |r,wU:14.15,wD:11.11,(7.66,4.8,;8.99,4.03,;8.99,2.49,;10.33,1.72,;11.66,2.49,;11.66,4.03,;10.33,4.8,;10.33,6.34,;7.66,1.72,;7.66,.18,;6.32,2.49,;4.99,1.72,;3.66,2.49,;2.32,1.72,;2.32,.18,;.99,-.59,;-.34,.18,;-1.68,-.59,;-3.03,.14,;-4.45,-.46,;-4.86,-2.02,;-6.32,-2.49,;-6.32,-4.03,;-7.66,-4.8,;-8.99,-4.03,;-10.33,-4.8,;-11.66,-4.03,;-10.33,-6.34,;-11.66,-5.57,;-4.86,-4.51,;-3.95,-3.26,;-2.42,-3.26,;-1.4,-2.1,;3.66,-.59,;4.99,.18,)| Show InChI InChI=1S/C24H31F3N4O3S/c1-30-19(3-2-4-21(30)32)22(33)28-17-7-5-16(6-8-17)9-12-31-13-10-18-20(11-14-31)35-23(29-18)34-15-24(25,26)27/h2-4,16-17H,5-15H2,1H3,(H,28,33)/t16-,17- | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
DrugBank antibodypedia GoogleScholar AffyNet ![](/images/AffyNet_logo.png)
| PC cid PC sid UniChem
| | 370 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA
| |
Citation and Details
|
More data for this Ligand-Target Pair | |
D(2) dopamine receptor
(Homo sapiens (Human)) | BDBM476772
![PNG](/data/jpeg/tenK47/BindingDB_476772.png) (US10870660, Compound III-128 | US11345716, Compoun...)Show SMILES Cn1c(cccc1=O)C(=O)N[C@H]1CC[C@H](CCN2CCc3nc(OCC(F)(F)F)sc3CC2)CC1 |r,wU:14.15,wD:11.11,(7.66,4.8,;8.99,4.03,;8.99,2.49,;10.33,1.72,;11.66,2.49,;11.66,4.03,;10.33,4.8,;10.33,6.34,;7.66,1.72,;7.66,.18,;6.32,2.49,;4.99,1.72,;3.66,2.49,;2.32,1.72,;2.32,.18,;.99,-.59,;-.34,.18,;-1.68,-.59,;-3.03,.14,;-4.45,-.46,;-4.86,-2.02,;-6.32,-2.49,;-6.32,-4.03,;-7.66,-4.8,;-8.99,-4.03,;-10.33,-4.8,;-11.66,-4.03,;-10.33,-6.34,;-11.66,-5.57,;-4.86,-4.51,;-3.95,-3.26,;-2.42,-3.26,;-1.4,-2.1,;3.66,-.59,;4.99,.18,)| Show InChI InChI=1S/C24H31F3N4O3S/c1-30-19(3-2-4-21(30)32)22(33)28-17-7-5-16(6-8-17)9-12-31-13-10-18-20(11-14-31)35-23(29-18)34-15-24(25,26)27/h2-4,16-17H,5-15H2,1H3,(H,28,33)/t16-,17- | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
DrugBank antibodypedia GoogleScholar AffyNet ![](/images/AffyNet_logo.png)
| PC cid PC sid UniChem
| US Patent
| 370 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
SHIONOGI & CO., LTD.
US Patent
| Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent... |
US Patent US10870660 (2020)
|
More data for this Ligand-Target Pair | |